Investment ThemesDetailed Quotes
Gene Editing Watchlist

Gene Editing is the ability to make highly specific changes in the DNA sequence of a living organism, essentially customizing its genetic makeup. It demonstrates great potential in gene research, gene therapy and genetic improvement. The Gene Editing concept includes major US-listed companies whose businesses are involved in gene editing.

  • 1307.745
  • -6.790-0.52%
Trading Jan 14 11:57 ET
1318.487High1306.850Low
Constituent Stocks: 10Top Rising: SGMO+1.85%
Intraday
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y
Constituent Stocks
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
WatchlistPaper Trade
SGMOSangamo Therapeutics
1.1000.020+1.85%1.46M1.64M1.1201.0801.1801.100229.51M224.44M208.65M204.04M-18.52%-57.03%-42.41%+10.89%+174.11%+135.39%+7.84%--0.71%LossLoss7.41%Biotechnology
CRBUCaribou Biosciences
1.5550.005+0.32%799.60K1.27M1.5801.5501.6301.555140.81M126.85M90.55M81.58M-17.29%-6.89%-19.85%-24.51%-35.21%-70.32%-2.20%--0.98%LossLoss4.84%Biotechnology
APLSApellis Pharmaceuticals
28.570-0.020-0.07%501.70K14.50M29.25028.59029.25028.5603.55B2.41B124.39M84.30M-16.90%-12.58%-12.74%+2.22%-22.53%-56.91%-10.47%--0.60%LossLoss2.41%Biotechnology
VRTXVertex Pharmaceuticals
411.945-1.425-0.34%340.14K140.10M411.940413.370413.790408.220106.09B105.78B257.53M256.79M+2.35%+0.78%-11.24%-15.46%-15.98%-5.84%+2.30%--0.13%Loss29.661.35%Biotechnology
EDITEditas Medicine
1.155-0.005-0.43%951.19K1.10M1.1601.1601.1901.13095.34M89.31M82.55M77.32M-19.23%-4.55%-38.89%-66.52%-79.41%-86.92%-9.06%--1.23%LossLoss5.17%Biotechnology
AAgilent Technologies
141.290-0.660-0.46%434.42K62.10M142.410141.950144.530141.18040.35B40.20B285.60M284.52M+3.56%+4.43%+0.45%+1.75%+8.52%+9.00%+5.17%0.67%0.15%31.8931.892.36%Diagnostics & Research
CRSPCRISPR Therapeutics
38.620-0.230-0.59%522.63K20.58M39.62038.85040.19038.6003.30B3.24B85.35M83.93M-8.98%-3.50%-14.93%-21.18%-32.47%-39.11%-1.88%--0.62%LossLoss4.09%Biotechnology
NTLAIntellia Therapeutics
9.795-0.255-2.54%913.75K9.11M10.11010.05010.3909.760997.61M982.68M101.85M100.32M-23.48%-18.17%-27.77%-52.41%-62.98%-63.40%-15.99%--0.91%LossLoss6.27%Biotechnology
BLUEbluebird bio
8.080-0.410-4.83%75.70K629.04K8.4908.4908.7508.06078.55M78.17M9.72M9.67M-18.55%-7.97%+6.31%-16.15%-67.42%-71.75%-3.12%--0.78%LossLoss8.13%Biotechnology
BEAMBeam Therapeutics
23.450-2.090-8.18%954.38K22.85M25.50025.54025.61523.0701.94B1.61B82.81M68.57M-11.04%-11.81%-16.43%-12.14%-22.66%-6.57%-5.44%--1.39%LossLoss9.97%Biotechnology

Comments

    $Editas Medicine (EDIT.US)$
    Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities
    Monday, 13th January at 9:00 am
    • Achieved in vivo preclinical proof of concept of editing hematopoietic stem cells in non-human primates as a key step toward developing a novel in vivo treatment for sickle cell disease and beta thalassemia
    • Achieved in vivo editing of liver cells in non-human primates and in vivo deliver...
    $Caribou Biosciences (CRBU.US)$
    Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025
    Sunday, 12th January at 7:05 pm
    -- CB-010 GALLOP Phase 1 trial initiated in lupus --
    -- CB-012 AMpLify Phase 1 trial in r/r AML completes dose level 3 with no DLTs; enrolling patients at dose level 4 --
    -- CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 --
    -- Sri Ryali appointed chief fi...
    4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway | 4D Molecular Therapeutics
    1
    because most people only share their wins to rub it in here are my biggest losses so far to show that I'm not winning  all the time or that I'm some kind of guru or expert trader that never loses markets go up and down all the time the important thing here is correct position size, and risk management. let us remember that the first loss will always the smallest lose to continue holding to a losing position only adds to the pain and doubt about our abilities. its best to live to trade anoth...
    loses
    5
Read more